Australian Other Utilities Stock News

Resolute Mining Limited recently reported half-year results for the period ended June 30, 2026, with net income rising to US$128.2 million and basic earnings per share from continuing operations increasing to US$0.0594, while also reaffirming 2026 production guidance toward the lower end of its 250 koz to 275 koz range and maintaining Group AISC guidance of US$2,000/oz to US$2,200/oz, subject to shifts in gold prices and fuel costs. The combination of significantly higher profitability and...

Shriro Holdings Limited ( ASX:SHM ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is two...

Bathurst Resources Limited ( ASX:BRL ) investors will be delighted, with the company turning in some strong numbers...

Last week saw the newest full-year earnings release from Sports Entertainment Group Limited ( ASX:SEG ), an important...

The latest analyst coverage could presage a bad day for Rubicon Water Limited ( ASX:RWL ), with the covering analyst...

Shareholders might have noticed that Macquarie Technology Group Limited ( ASX:MAQ ) filed its yearly result this time...

Shareholders might have noticed that Kelsian Group Limited ( ASX:KLS ) filed its full-year result this time last week...

Paragon Care Limited ( ASX:PGC ) came out with its full-year results last week, and we wanted to see how the business...

Vault Minerals Limited recently reported full-year results for the 12 months to June 30, 2026, with sales of A$1,926.61 million and net income of A$278.41 million, both higher than the prior year. Basic earnings per share from continuing operations rose to A$0.267, underscoring improved profitability and operational efficiency across the business. We’ll now look at how this earnings growth, particularly the rise in net income, shapes Vault Minerals’ broader investment narrative. We've...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers. For long term holders, the key point is that this remains a highly...

Insiders who purchased AU$1.36m worth of Credit Clear Limited ( ASX:CCR ) shares over the past year recouped some of...

McMillan Shakespeare stock has been grinding higher in recent months, yet the real story today is not the share price at A$20.87. The real story is a profit engine that just posted record underlying net profit after tax and amortisation of A$107.9m and a fatter 41.5% operating margin in a year that was meant to be tougher for salary packaging and fleet services. For investors, the kicker is the cash being returned. The board signed off on a fully franked full year dividend of A$1.32 per...

Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...

Emerald Resources NL ( ASX:EMR ) came out with its yearly results last week, and we wanted to see how the business is...

It looks like Monadelphous Group Limited ( ASX:MND ) is about to go ex-dividend in the next four days. The ex-dividend...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Weebit Nano shareholders have watched the stock slide in recent months, with the price now at A$3.75 after a tough 90 days. Today's full year numbers keep that pressure squarely on profitability. Revenue for FY 2026 remains modest at A$15.28m on a trailing twelve month basis, while losses from continuing operations widened to A$54.90m. For a pre revenue scale semiconductor player, this earnings release focuses on how long the company can fund that loss profile and how investors balance the...

Shaver Shop Group went into this result priced like a value play, with the stock at A$1.41 and a P/E of 12.5x that sat below peer and industry averages. The headline from the numbers is not a growth surge. It is a tension between record sales of A$225.1m and record gross margin of 46.3% on one side and essentially flat net profit after tax of A$14.8m on the other. That mix sets up a classic sentiment test. Traders focused only on headline records might cheer, while investors watching a 90%...

Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway. Concerned by Actinogen Medical's cash runway...

It's been a pretty great week for Perseus Mining Limited ( ASX:PRU ) shareholders, with its shares surging 10% to...

Why Sonic Healthcare’s latest earnings and dividend matter now Sonic Healthcare (ASX:SHL) has drawn fresh attention after releasing full year 2026 results, confirming higher revenue and net income than a year earlier, alongside a declared dividend for the June half. Sonic Healthcare’s share price has softened in the short term, with a 7 day share price return of 4.93% and a 30 day share price return of 11.8% down to A$20.04. The 1 year total shareholder return has declined 12.74%, pointing to...